Trevi Therapeutics Inc TRVI

NAS: TRVI | ISIN: US89532M1018 30/04/2025

6,910 USD (+9,51%)

(+9,51%) 30/04/2025

Grafiek Trevi Therapeutics Inc

Grafiek Trevi Therapeutics Inc

1 dag1d 9,51%
1 week1w 8,82%
1 maand1m 14,98%
3 maanden3m 63,74%
6 maanden6m 129,57%
1 jaar1j 141,61%
5 jaar5j 156,88%

Trevi Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

3 april 2025 · Trevi Therapeutics to Participate in Upcoming April Investor Conferences · Persbericht

18 maart 2025 · Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates · Persbericht

11 maart 2025 · Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 · Persbericht

10 maart 2025 · Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough · Persbericht

9 maart 2025 · Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough · Persbericht

4 september 2024 · Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 · Persbericht

28 augustus 2024 · Trevi Therapeutics to Participate in September Investor and Medical Conferences · Persbericht

8 augustus 2024 · Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance · Persbericht

1 augustus 2024 · Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 · Persbericht

2 juli 2024 · Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events · Persbericht

Profiel Trevi Therapeutics Inc

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 26

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe